Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Zalcberg

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
British Journal of Cancer|September 12, 2014
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancerM Michael, S Chander, J McKendrick, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancerM J Millward, J Zalcberg, J F Bishop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD GroupH Bleiberg, G Decoster, A de Gramont, et al.
BMC Cancer|December 13, 2023
Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancerS M Evans, K Ivanova, R Rome, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I studyH M Prince, M J Millward, D Rischin, et al.
Thoracic Cancer|June 16, 2025
Optimizing Pre-Operative Clinical Staging in Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Cohort StudyE Samuel, C Thomas, C Thompson, et al.
British Journal of Cancer|February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD databaseC S Karapetis, H Liu, M J Sorich, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
British Journal of Cancer|September 12, 2014
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancerM Michael, S Chander, J McKendrick, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancerM J Millward, J Zalcberg, J F Bishop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD GroupH Bleiberg, G Decoster, A de Gramont, et al.
BMC Cancer|December 13, 2023
Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancerS M Evans, K Ivanova, R Rome, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I studyH M Prince, M J Millward, D Rischin, et al.
Thoracic Cancer|June 16, 2025
Optimizing Pre-Operative Clinical Staging in Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Cohort StudyE Samuel, C Thomas, C Thompson, et al.
British Journal of Cancer|February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD databaseC S Karapetis, H Liu, M J Sorich, et al.
Pageof 7